Down-regulation of CD28 expression by TNF-α

被引:219
作者
Bryl, E
Vallejo, AN
Weyand, CM
Goronzy, JJ
机构
[1] Mayo Clin, Dept Med, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Immunol, Rochester, MN 55905 USA
关键词
D O I
10.4049/jimmunol.167.6.3231
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Aging and chronic inflammatory syndromes, such as rheumatoid arthritis, are associated with high frequencies of CD4(+)CD28(null) T cells, which are rarely seen in healthy individuals younger than 40 years. Inasmuch as rheumatoid arthritis and aging are also associated with elevated levels of TNF-alpha, we examined whether this proinflammatory cytokine influences CD28 expression. Incubation of T cell lines and clones as well as Jurkat cells with TNF-alpha induced a reduction in the levels of cell surface expression of CD28. This effect of TNF-alpha was reversible; however, continuous culture of CD4(+)CD28(+) T cell clones in TNF-alpha resulted in the appearance of a CD28(null) subset. In reporter gene bioassays, TNF-alpha was found to inhibit the activity of the CD28 minimal promoter. Inactivation of the promoter was accompanied by a marked reduction in DNA-protein complex formation by two DNA sequence motifs corresponding to the transcriptional initiator of the CD28 gene. Indeed, in vitro transcription assays showed that nuclear extracts from TNF-alpha -treated cells failed to activate transcription of DNA templates under the control of a consensus TATA box and the CD28 initiator sequences. In contrast, similar extracts from unstimulated T cells supported transcription. These results demonstrate that TNF-alpha directly influences CD28 gene transcription. We propose that the emergence of CD4(+)CD28(null) T cells in vivo is facilitated by increased production of TNF-alpha.
引用
收藏
页码:3231 / 3238
页数:8
相关论文
共 58 条
[51]  
Vallejo AN, 1999, J IMMUNOL, V162, P6572
[52]   Functional disruption of the CD28 gene transcriptional initiator in senescent T cells [J].
Vallejo, AN ;
Weyand, CM ;
Goronzy, JY .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (04) :2565-2570
[53]  
VALLEJO AN, 1994, PCR METH APPL, V4, pS123
[54]   Tumor necrosis factor receptor and Fas signaling mechanisms [J].
Wallach, D ;
Varfolomeev, EE ;
Malinin, NL ;
Goltsev, YV ;
Kovalenko, AV ;
Boldin, MP .
ANNUAL REVIEW OF IMMUNOLOGY, 1999, 17 :331-367
[55]  
Wang IM, 1996, MOL CELL BIOL, V16, P6313
[56]   A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate [J].
Weinblatt, ME ;
Kremer, JM ;
Bankhurst, AD ;
Bulpitt, KJ ;
Fleischmann, RM ;
Fox, RI ;
Jackson, CG ;
Lange, M ;
Burge, DJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (04) :253-259
[57]   TRANSCRIPTION BY RNA POLYMERASE-II - INITIATOR-DIRECTED FORMATION OF TRANSCRIPTION-COMPETENT COMPLEXES [J].
WEIS, L ;
REINBERG, D .
FASEB JOURNAL, 1992, 6 (14) :3300-3309
[58]   Deletional and mutational analyses of the human CD4 gene promoter: characterization of a minimal tissue-specific promoter [J].
Zhao-Emonet, JC ;
Boyer, O ;
Cohen, JL ;
Klatzmann, D .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1998, 1442 (2-3) :109-119